MANNHEIM, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company ...

ALX Oncology Holdings (Nasdaq: ALXO), a Californian immuno-oncology company, has announced the appointment of Alan Sandler ... data analyses and commentary from our global network of life sciences ...

“HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary ...

“HBP0”) (“Helix” or the “Company), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 ...

Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 18 pharmaceutical deals announced in Q3 2024, worth a total value of $2.9bn. The $1.3bn acquisition of Nerio ...

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving cost savings—has evolved to include a fourth dimension: provider ...

Learn how to write a cover letter that leaves a great impression — and makes a potential employer want to know more about you.

A rare letter signed by three of the Founding Fathers of the United States is going on sale, and is expected to fetch up to $1 million when it goes under the hammer next week. Bearing the ...